Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's Disease
文献类型：期刊论文
| 作者 | Jin, Dan2,3,4 ; Zhou, Bo5; Han, Ying6; Ren, Jiaji2,3,4; Han, Tong7; Liu, Bing2,3,4,8; Lu, Jie9; Song, Chengyuan10; Wang, Pan11; Wang, Dawei16
|
| 刊名 | ADVANCED SCIENCE
 |
| 出版日期 | 2020-06-09 |
| 页码 | 12 |
| 关键词 | Alzheimer's disease computer-aided diagnosis neurobiological basis neuroscientifically interpretable biomarkers structural magnetic resonance imaging |
| DOI | 10.1002/advs.202000675 |
| 通讯作者 | Wang, Qing(wangqing663@163.com) ; Liu, Yong(yliu@nlpr.ia.ac.cn) |
| 英文摘要 | Precision medicine for Alzheimer's disease (AD) necessitates the development of personalized, reproducible, and neuroscientifically interpretable biomarkers, yet despite remarkable advances, few such biomarkers are available. Also, a comprehensive evaluation of the neurobiological basis and generalizability of the end-to-end machine learning system should be given the highest priority. For this reason, a deep learning model (3D attention network, 3DAN) that can simultaneously capture candidate imaging biomarkers with an attention mechanism module and advance the diagnosis of AD based on structural magnetic resonance imaging is proposed. The generalizability and reproducibility are evaluated using cross-validation on in-house, multicenter (n = 716), and public (n = 1116) databases with an accuracy up to 92%. Significant associations between the classification output and clinical characteristics of AD and mild cognitive impairment (MCI, a middle stage of dementia) groups provide solid neurobiological support for the 3DAN model. The effectiveness of the 3DAN model is further validated by its good performance in predicting the MCI subjects who progress to AD with an accuracy of 72%. Collectively, the findings highlight the potential for structural brain imaging to provide a generalizable, and neuroscientifically interpretable imaging biomarker that can support clinicians in the early diagnosis of AD. |
| WOS关键词 | MILD COGNITIVE IMPAIRMENT ; RESTING-STATE FMRI ; CLASSIFICATION ; ATROPHY ; RISK ; MRI ; HIPPOCAMPAL ; PERFORMANCE ; PREDICTION ; NETWORK |
| 资助项目 | National Key Research and Development Program of China[2016YFC1305904] ; National Key Research and Development Program of China[2018YFC2001700] ; Strategic Priority Research Program (B) of the Chinese Academy of Sciences[XDB32020200] ; National Natural Science Foundation of China[81871438] ; National Natural Science Foundation of China[81901101] ; National Natural Science Foundation of China[61633018] ; National Natural Science Foundation of China[81571062] ; National Natural Science Foundation of China[81400890] ; National Natural Science Foundation of China[81471120] ; National Natural Science Foundation of China[81701781] ; Medical Big Data R&D Project of the PLA General Hospital[2018MBD028] ; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)[U01 AG024904] ; DOD ADNI (Department of Defense)[W81XWH-12-2-0012] ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; AbbVie ; Alzheimer's Association ; Alzheimer's Drug Discovery Foundation ; Araclon Biotech ; BioClinica, Inc. ; Biogen ; Bristol-Myers Squibb Company ; CereSpir, Inc. ; Cogstate ; Eisai Inc. ; Elan Pharmaceuticals, Inc. ; Eli Lilly and Company ; EuroImmun ; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc. ; Fujirebio ; GE Healthcare ; IXICO Ltd. ; Janssen Alzheimer Immunotherapy Research & Development, LLC. ; Johnson & Johnson Pharmaceutical Research & Development LLC. ; Lumosity ; Lundbeck ; Merck Co., Inc. ; Meso Scale Diagnostics, LLC. ; NeuroRx Research ; Neurotrack Technologies ; Novartis Pharmaceuticals Corporation ; Pfizer Inc. ; Piramal Imaging ; Servier ; Takeda Pharmaceutical Company ; Transition Therapeutics ; Canadian Institutes of Health Research |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000538998400001 |
| 资助机构 | National Key Research and Development Program of China ; Strategic Priority Research Program (B) of the Chinese Academy of Sciences ; National Natural Science Foundation of China ; Medical Big Data R&D Project of the PLA General Hospital ; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) ; DOD ADNI (Department of Defense) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; AbbVie ; Alzheimer's Association ; Alzheimer's Drug Discovery Foundation ; Araclon Biotech ; BioClinica, Inc. ; Biogen ; Bristol-Myers Squibb Company ; CereSpir, Inc. ; Cogstate ; Eisai Inc. ; Elan Pharmaceuticals, Inc. ; Eli Lilly and Company ; EuroImmun ; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc. ; Fujirebio ; GE Healthcare ; IXICO Ltd. ; Janssen Alzheimer Immunotherapy Research & Development, LLC. ; Johnson & Johnson Pharmaceutical Research & Development LLC. ; Lumosity ; Lundbeck ; Merck Co., Inc. ; Meso Scale Diagnostics, LLC. ; NeuroRx Research ; Neurotrack Technologies ; Novartis Pharmaceuticals Corporation ; Pfizer Inc. ; Piramal Imaging ; Servier ; Takeda Pharmaceutical Company ; Transition Therapeutics ; Canadian Institutes of Health Research |
| 源URL | [http://ir.ia.ac.cn/handle/173211/39822]  |
| 专题 | 自动化研究所_脑网络组研究中心 |
| 通讯作者 | Wang, Qing; Liu, Yong |
| 作者单位 | 1.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China 2.Chinese Acad Sci, Inst Automat, Brainnetome Ctr, Beijing 100190, Peoples R China 3.Chinese Acad Sci, Inst Automat, Natl Lab Pattern Recognit, Beijing 100190, Peoples R China 4.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing 100049, Peoples R China 5.Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Med Ctr 2, Dept Neurol, Beijing 100853, Peoples R China 6.Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China 7.Tianjin Huanhu Hosp, Dept Radiol, Tianjin 300350, Peoples R China 8.Chinese Acad Sci, Inst Automat, Ctr Excellence Brain Sci & Intelligence Technol, Beijing 100190, Peoples R China 9.Capital Med Univ, Xuanwu Hosp, Dept Radiol, Beijing 100053, Peoples R China 10.Shandong Univ, Qilu Hosp, Dept Neurol, Jinan 250012, Peoples R China |
| 推荐引用方式 GB/T 7714 | Jin, Dan,Zhou, Bo,Han, Ying,et al. Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's Disease[J]. ADVANCED SCIENCE,2020:12. |
| APA | Jin, Dan.,Zhou, Bo.,Han, Ying.,Ren, Jiaji.,Han, Tong.,...&Liu, Yong.(2020).Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's Disease.ADVANCED SCIENCE,12. |
| MLA | Jin, Dan,et al."Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's Disease".ADVANCED SCIENCE (2020):12. |
入库方式： OAI收割
来源：自动化研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。